Editor's PickMarket News

Mountain Valley MD says it has received approval from the Canadian Intellectual Property Office for the patent filing around its Quicksome technology

Mountain Valley MD Holdings Inc. (CSE:MVMD) (FRA:20MP) said it has received approval from the Canadian Intellectual Property Office for the patent filing around its Quicksome technology. The company’s patented Quicksome liposome technology utilizes an advanced two-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral product formats. The technology is being applied across a variety of vaccine, drug and nutraceutical application. READ: Mountain Valley MD submits application to list on the OTCQB market in New York “The ongoing acceptance of our patents across numerous continents is a validation of the uniqueness of our Quicksome technology and our proprietary approach to deliver complex molecules into the body more effectively,” said Mike Farber, director of Life Sciences for Mountain Valley MD in a statement. “This formally allows us to develop exclusive products in Canada that deliver superior pharmacokinetic performance without competitive interference,” he added. The company released pre-clinical trial data on December 10, 2020, where a solubilized version of the drug Ivermectin was administered via its Quicksome desiccated liposome technology as compared to an existing oral Ivermectin solution.   The results demonstrated that the Quicksome technology was able to successfully administer Ivermectin across the mucosa, with a significant improvement in the pharmacokinetic performance compared to current oral formats. The pre-clinical data included: a 500% increase in bioavailability compared to oral tablets, a TMAX (the time to reach the maximum concentration in the body) of 1 hour, a 600% increase over oral tablets, zero decline in CMAX (peak serum concentration that a drug achieves) over the entire 6-hour period investigated, and only 5% variability compared to 40% variability for oral tablets. “Building our global patent portfolio is a very important part of MVMD’s business strategy. The allowance of this patent in Canada is a great validation of our unique product advantages and this award helps the Company continue to protect our unique competitive advantages,” said Dennis Hancock, president & CEO of Mountain Valley MD. “Our ongoing focus on creating shareholder value through significant transformational health and wellness pursuits is firmly anchored in our ability to protect our technology leadership.” Mountain Valley MD is building a world-class biotech and life sciences company organization centred around the implementation of its patented Quicksome oral drug formulation and delivery technologies and its Quicksol solubilization technology for macrocyclic lactones, to innovate industry-leading products that are sought out globally. Contact the author at jon.hopkins@proactiveinvestors.com

Leave a Reply

Your email address will not be published. Required fields are marked *